Oncology

Fragmentation in oncology care significantly influences physicians’, payers’, and patients’ understanding of how cancer therapies lead to improved quality of care.

An expanding role for oncology pharmacy in the optimization of cancer care is likely to emerge over the next 3 to 5 years, as payers seek better outcomes for their money.

Both practice guidelines and thought leaders increasingly recommend biomarker tests for optimization of cancer care; there is, however, a gap between these recommendations, the way physicians practice, and the way they think they practice.